Research Priorities in the Management of Hidradenitis Suppurativa.

Paul Leighton¹, ORCID = 0000-0001-5208-0274
Laura Howells¹, ORCID = 0000-0003-4157-7394
Janine Bates², ORCID = 0000-0003-3610-2415;
Angela Gibbons³, ORCID = 0000-0001-5285-4954
Rebecca Cannings-John², ORCID= 0000-0001-5235-6517
Fiona Collier⁴,
Judith Evans²,
Ceri Harris³, ORCID = 0000-0002-0462-7789
Kerry Hood⁵, ORCID = 0000-0002-5268-8631
Rachel Howes⁶,
Muhammad Riaz², ORCID = 0000-0002-5512-1745
Jeremy Rodrigues⁶,⁷, ORCID = 0000-0002-9347-5026
Helen Stanton², ORCID= 0000-0003-0197-3667
Emma Thomas-Jones², ORCID = 0000-0001-7716-2786
Kim Thomas²,ORCID = 0000-0001-7785-7465
John R Ingram⁸. ORCID = 0000-0002-5257-1142

1. Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham.
2. Centre for Trials Research, College of Biomedical & Life Sciences, Cardiff University.
3. Public Contributors.
4.
5.
6. Warwick Clinical Trials Unit, University of Warwick
7. Dept of Plastic Surgery, Stoke Mandeville Hospital, Buckinghamshire Healthcare Trust
8. Division of Infection & Immunity, Cardiff University.
Acknowledgements:

We would like to thank and acknowledge all those that participated in the meeting. This includes: Samantha Butters, Sarah Carroll, Samar Hasan, Gemma Howard, Emma McMullen, Tim Pickles, Mark Rendall, and Jo Wilson.
Dear Editor

There is a need for high quality research evidence to support the management of hidradenitis suppurativa (HS) (1, 2).

The Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS) seeks to contribute to this agenda by informing “the design of future HS Randomised Controlled Trials (RCTs)” (3). Its objectives include characterising potential study interventions, determining current patient pathways, contributing to the validation of a core outcome set (4), and establishing the feasibility of future trial recruitment (3). In this article we provide an early report of one aspect of its work – a consensus meeting to prioritise future HS RCT designs.

In June 2022 a hybrid consensus meeting was hosted by the THESEUS team. Thirty individuals participated, including 7 healthcare professionals, 10 researchers, and 13 people living with HS. Fourteen of these joined online via the zoom platform (including 7 people with HS).

A list of possible pairwise HS treatment comparisons was the focus of the meeting. These comparisons were informed by clinical guidelines and the THESEUS programme of work to date.

The meeting took place in a single day and followed the nominal group technique (5). Prior to the meeting participants were asked, via an online form, to identify up to three treatment comparisons where future research would be valued. During the meeting, small group and whole group discussion (followed by scoring) identified a smaller number of preferred trials before finalising a set of priority trials.

Figure 1 shows the transition from twelve trials to three prioritised trials.

It is of note that Option F (“Early intervention usually used later in treatment in care pathway”) was considered to generically capture the specifics of other options, so despite an agreement about its importance it was not carried forward. Early intervention to prevent longer term consequences was thought an important goal for future HS research.

Early discussion also led to Options C (Laser versus clindamycin and rifampicin) and D (Clindamycin and rifampicin + laser compared to clindamycin and rifampicin alone) being merged to a new Option M: “clindamycin & rifampicin + laser v. laser alone”.

Four options were preferred following discussion, Options K (Adalimumab + laser compared to Adalimumab alone), E (Deroofing of skin tunnels compared to local excision surgery), L (Adalimumab + deroofing compared to Adalimumab alone) and Option M.

In the final scoring three prioritised options were identified: Option K gained 25 votes (50% of the votes cast), M 16 votes (32%) and E 8 votes (16%); Option L received only 1 vote (2%). All bar two individuals living with HS selected Option K as one of their choices, 75% of votes for Option E (6/8) were from individuals living with HS.

Discussion suggested that increasing access to treatments that are not commonly available in the UK was a factor in prioritising deroofing, laser hair removal and biologics. Alongside this, it was considered important that research should be widely accessible and benefit a broad spectrum of individuals living with HS.

The priority offered to laser treatment (in Options C, D, F and M), in parallel with a desire for wide-reaching research, might suggest a broad comparison of laser plus medical treatment versus medical treatment alone or laser treatment alone. A multi-arm study design that allows for different medical

treatments for people at different stages/severity of disease could build the evidence base for laser treatment in a broad and inclusive fashion.

Geographic variation in treatment availability was recognised and improved treatment accessibility was considered an important goal for any HS future research. The potential for HS flare-clinics was recognised in this – supporting quicker access to appropriate healthcare for those experiencing a HS flare.

Before concluding we should recognise some limitations in our method. Participants may not be fully representative – only one GP participated, and many of those with lived experience had already experienced multiple treatments. Whilst the hybrid meeting supported broad participation it may be that those joining online were less able to directly contribute.

This workshop was intended as a springboard for designing future HS RCTs. It builds upon insight gained during the THESEUS study and benefits from the participation of the network of clinicians, researchers, and members of the public involved in the delivery of THESEUS. With a network of potential recruiting centres already in place the THESEUS team are now well placed to develop the prioritised trials. We would encourage other researchers to consider the trial comparisons prioritised in our meeting as ways in which the treatment of HS might be advanced and improved.

Figure 1: from original list to prioritised trials.

original list - not carried forward

• A: Clindamycin & rifampicin compared to doxycycline
• B: Higher dose of standard medical treatment (e.g. doxycycline, clindamycin & rifampicin or other tablet treatment) compared to standard/lower dose
• C: Laser (hair removal) versus clindamycin & rifampicin
• D: Clindamycin & rifampicin + laser (hair removal) compared to clindamycin & rifampicin alone
• F: Early intervention with treatment usually used later in care pathway (e.g. biologics) compared to doxycycline
  • G: Metformin compared to doxycycline
  • H: Spironolactone compared to doxycycline
  • I: Metformin compared to Clindamycin & rifampicin
  • J: Adalimumab (or biosimilar) compared to clindamycin & rifampicin

preferred - not prioritised

L: Adalimumab (or biosimilar) + deroofing skin tunnels compared to Adalimumab (or biosimilar) alone

PRIORITISED

• K: Adalimumab (or biosimilar) + laser (hair removal) compared to Adalimumab (or biosimilar) alone
  
M: Clindamycin & rifampicin + laser (hair removal) compared to laser alone

E: Deroofing of skin tunnels compared to local excision surgery

Refs:


